Citations

Clear

3138 citation(s) found for "Smith, AM".

Importance of Routine Antihuman/Leukocyte Antibody Monitoring
Wong, Ka Lam , Taner, Timuçin , Kushwaha, Sudhir S. , Edwards, Brooks S., Gandhi, Manish J. , Kremers, Walter K. , Daly, Richard C. , Pereira, Naveen L. , Wong, Ka L, Smith, Byron H. , Kremers, Walter K

Mayo Clinic

Circulation | October 2, 2017 | Volume: 136 | Issue: 14 | Pages: 1350-1352

10.1161/circulationaha.117.029964 | PMID 28972064 Get It

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Campone, Mario , Sohn, Joohyuk , Paluch–Shimon, Shani , Huober, Jens , Park, In Hae , Trédan, Olivier , Chen, Shin‐Cheh , Manso, Luís , Freedman, Orit, Jaliffe, Georgina Garnica, Forrester, Tammy , Frenzel, Martin, Barriga, Susana , Bourayou, Nawel, Leo, Angelo Di , Toi, Masakazu , Paluch-Shimon, Shani, Freedman, Orit C, Garnica Jaliffe, Georgina, Smith, Ian C., Di Leo, Angelo, Hae Park, In , Di Leo, Angelo , Goetz, Matthew P. , Smith, Ian C., Manso Sanchez, Luis , Sohn, Joohyuk

Mayo Clinic

Journal of Clinical Oncology | October 2, 2017 | Volume: 35 | Issue: 32 | Pages: 3638-3646

10.1200/jco.2017.75.6155 | PMID 28968163 Get It

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm ( P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
Faculty Opinions recommendation of Cutting edge: dual tcrα expression poses an autoimmune hazard by limiting regulatory T cell generation.
Shapiro, Virginia Smith

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 20, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727650337.793536656 Get It

Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality
Secreto, Frank J., Smith, Alyson , Bruinsma, Elizabeth S. , Perales‐Clemente, Ester , Oommen, Saji , Hawse, Gresin, Hrstka, Sybil , Arendt, Bonnie K., Brandt, Emma B. , Wigle, Dennis A. , Smith, Alyson J, Perales-Clemente, Ester, Hrstka, Sybil C L, Nelson, Timothy J , Li, Xing , Hawse, Gresin P. , Nelson, Timothy J. , Hrstka, Sybil C

Mayo Clinic

Stem Cells Translational Medicine | September 19, 2017 | Volume: 6 | Issue: 10 | Pages: 1829-1839

10.1002/sctm.17-0116 | PMID 28924979 Get It

Abstract Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells’ documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of <300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells.
St. Louis encephalitis virus possibly transmitted through blood transfusion—Arizona, 2015
Venkat, Heather , Adams, Laura E. , Sunenshine, Rebecca, Krow‐Lucal, Elisabeth , Levy, Craig, Kafenbaum, Tammy, Sylvester, Tammy, Smith, Kirk, Townsend, John, Dosmann, Melissa, Kamel, Hany , Patron, Roberto L. , Kuehnert, Matthew J. , Annambhotla, Pallavi , Basavaraju, Sridhar V. , Rabe, Ingrid B., Team, SLEV Transmission Investigation, Patron, Roberto, Townsend, John, Team, SLEV Transmission Investigation

Mayo Clinic

Transfusion | September 14, 2017 | Volume: 57 | Issue: 12 | Pages: 2987-2994

10.1111/trf.14314 | PMID 28905395 Get It

BACKGROUNDSt. Louis encephalitis virus is a mosquito‐borne flavivirus that infrequently causes epidemic central nervous system infections. In the United States, blood donors are not screened for St. Louis encephalitis virus infection, and transmission through blood transfusion has not been reported. During September 2015, St. Louis encephalitis virus infection was confirmed in an Arizona kidney transplant recipient. An investigation was initiated to determine the infection source.STUDY DESIGN AND METHODSThe patient was interviewed, and medical records were reviewed. To determine the likelihood of mosquito‐borne infection, mosquito surveillance data collected at patient and blood donor residences in timeframes consistent with their possible exposure periods were reviewed. To investigate other routes of exposure, organ and blood donor and recipient specimens were obtained and tested for evidence of St. Louis encephalitis virus infection.RESULTSThe patient presented with symptoms of central nervous system infection. Recent St. Louis encephalitis virus infection was serologically confirmed. The organ donor and three other organ recipients showed no laboratory or clinical evidence of St. Louis encephalitis virus infection. Among four donors of blood products received by the patient via transfusion, one donor had a serologically confirmed, recent St. Louis encephalitis virus infection. Exposure to an infected mosquito was unlikely based on the patient's minimal outdoor exposure. In addition, no St. Louis encephalitis virus‐infected mosquito pools were identified around the patient's residence.CONCLUSIONThis investigation provides evidence of the first reported possible case of St. Louis encephalitis virus transmission through blood product transfusion. Health care providers and public health professionals should maintain heightened awareness for St. Louis encephalitis virus transmission through blood transfusion in settings where outbreaks are identified.
Increased Incidence of Loco-Regional Recurrences among African American Women with Terminal Stage Breast Cancer
Colón‐Otero, Gerardo , King, Sherry, Smith, Vandelyn, Bieber, Carolyn, Shannon, Robert P. , Perez, Edith A. , Crook, Julia E. , Solberg, Lawrence A.

Mayo Clinic

Clinical medicine. Oncology | September 14, 2017 | Volume: 2 | Issue: No issue available | Pages: No page available

10.4137/cmo.s988 | PMID 21892330 Get It

A prospective analysis of women with terminal breast cancer admitted to CHNE from November 2006-August 2007 evaluated anecdotal observations that African American (AA) women are likelier than Caucasian women to evidence loco-regional recurrences (LRR). Women with terminal breast cancer who were admitted to CHNE, a not-for-profit hospice serving over 90% of Northeast Florida hospice patients, were eligible for participation. 134 terminal breast cancer patients were assessed by hospice nurses for LRR presence via chest wall examination. 80% of them (107) were Caucasian, 17% (23) were AA and 3% (4) were of other ethnicities. Evidence of LRR were noted in 13% of the women (17/134). The proportion of patients with LRR was higher in AA women than Caucasian women (26% vs. 10%, 6/23 vs. 11/107, respectively), although this difference was not statistically significant (p = 0.08). The majority of Caucasian women with LRR consented to a medical record review, but a minority of AA women consented (8/11 vs. 2/6, respectively, p = 0.16). Conclusion Evaluating disparities in breast cancer care outcomes is possible by reviewing data from patients served by hospice programs that aid a majority of patients within a community. This pilot data suggests that AA women with breast cancer have a higher incidence of loco-regional failure as a component of their terminal breast cancer disease than Caucasian women. A smaller proportion of AA patients and families agreed to participate in a medical record review study than Caucasians. Larger studies are necessary to confirm these findings, to elucidate factors contributing to disparities and to develop potential solutions.
Nursing Home Use Across The Spectrum of Cognitive Decline: Merging Mayo Clinic Study of Aging With CMS MDS Assessments
Emerson, Jane A., Long, Kirsten Hall , Ransom, Jeanine E. , Roberts, Rosebud O., Duhig, Amy, Petersen, Ronald C. , Leibson, Cynthia L., Smith, Carin Y. , Hass, Steven

Mayo Clinic

Journal of the American Geriatrics Society | September 11, 2017 | Volume: 65 | Issue: 10 | Pages: 2235-2243

10.1111/jgs.15022 | PMID 28892128 Get It

Background/objectives Objective, complete estimates of nursing home ( NH ) use across the spectrum of cognitive decline are needed to help predict future care needs and inform economic models constructed to assess interventions to reduce care needs. Design Retrospective longitudinal study. Setting Olmsted County, MN . Participants Mayo Clinic Study of Aging participants assessed as cognitively normal ( CN ), mild cognitive impairment ( MCI ), previously unrecognized dementia, or prevalent dementia (age = 70–89 years; N = 3,545). Measurements Participants were followed in Centers for Medicare and Medicaid Services (CMS) Minimum Data Set (MDS) NH records and in Rochester Epidemiology Project provider‐linked medical records for 1‐year after assessment of cognition for days of observation, NH use (yes/no), NH days, NH days/days of observation, and mortality. Results In the year after cognition was assessed, for persons categorized as CN , MCI , previously unrecognized dementia, and prevalent dementia respectively, the percentages who died were 1.0%, 2.6%, 4.2%, 21%; the percentages with any NH use were 3.8%, 8.7%, 19%, 40%; for persons with any NH use, median NH days were 27, 38, 120, 305, and median percentages of NH days/days of observation were 7.8%, 12%, 33%, 100%. The year after assessment, among persons with prevalent dementia and any NH use, >50% were a NH resident all days of observation. Pairwise comparisons revealed that each increase in cognitive impairment category exhibited significantly higher proportions with any NH use. One‐year mortality was especially high for persons with prevalent dementia and any NH use (30% vs 13% for those with no NH use); 58% of all deaths among persons with prevalent dementia occurred while a NH resident. Conclusions Findings suggest reductions in NH use could result from quality alternatives to NH admission, both among persons with MCI and persons with dementia, together with suitable options for end‐of‐life care among persons with prevalent dementia.
C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity
Lee, Youn‐Bok , Baskaran, Pranetha , Gomez-Deza, Jorge, Nishimura, Agnes L. , Smith, Bradley , Troakes, Claire , Adachi, Yoshitsugu, Stepto, Alan, Petrucelli, Leonard , Gallo, Jean‐Marc , Hirth, Frank , Rogelj, Boris , Guthrie, Sarah , Shaw, Christopher E. , Chen, Han-Jou , Troakes, Claire

Mayo Clinic

Human Molecular Genetics | September 11, 2017 | Volume: 26 | Issue: 24 | Pages: 4765-4777

10.1093/hmg/ddx350 | PMID 28973350 Get It

Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype
Gerkin, Richard C. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Dugger, Brittany N. , Belden, Christine M. , Smith, Brian H. , Sue, Lucia I., Davis, Kathryn, Zamrini, Edward , Beach, Thomas G. , Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel , Serrano, Geidy E. , Dugger, Brittany N

Mayo Clinic

Annals of Clinical and Translational Neurology | September 8, 2017 | Volume: 4 | Issue: 10 | Pages: 714-721

10.1002/acn3.447 | PMID 29046880 Get It

AbstractObjectiveTo assess the predictive potential of the complete response pattern from the University of Pennsylvania Smell Identification Test for the diagnosis of Parkinson's disease.MethodsWe analyzed a large dataset from the Arizona Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study of health and disease in elderly volunteers. Using the complete pattern of responses to all 40 items in each subject's test, we built predictive models of neurodegenerative disease, and we validated these models out of sample by comparing model predictions against postmortem pathological diagnosis.ResultsConsistent with anatomical considerations, we found that the specific test response pattern had additional predictive power compared with a conventional measure – total test score – in Parkinson's disease, but not Alzheimer's disease. We also identified specific test questions that carry the greatest predictive power for disease diagnosis.InterpretationOlfactory ability has typically been assessed with either self‐report or total score on a multiple choice test. We showed that a more accurate clinical diagnosis can be made using the pattern of responses to all the test questions, and validated this against the “gold standard” of pathological diagnosis. Information in the response pattern also suggests specific modifications to the standard test that may optimize predictive power under the typical clinical constraint of limited time. We recommend that future studies retain the individual item responses for each subject, and not just the total score, both to enable more accurate diagnosis and to enable additional future insights.
Computer versus Compensatory Calendar Training in Individuals with Mild Cognitive Impairment: Functional Impact in a Pilot Study
Chandler, Melanie , Duncan, Noah, Hanna, Sherrie , Cuc, Andrea , Fields, Julie A. , Hoffman‐Snyder, Charlene , Lunde, Angela , Chandler, Melanie J, Locke, Dona E.C. , Hanna, Sherrie M, Cuc, Andrea V , Hoffman Snyder, Charlene R, Lunde, Angela M, Smith, Glenn E.

Mayo Clinic

Brain Sciences | September 6, 2017 | Volume: 7 | Issue: 9 | Pages: 112

10.3390/brainsci7090112 | PMID 28878146 Get It

This pilot study examined the functional impact of computerized versus compensatory calendar training in cognitive rehabilitation participants with mild cognitive impairment (MCI). Fifty-seven participants with amnestic MCI completed randomly assigned calendar or computer training. A standard care control group was used for comparison. Measures of adherence, memory-based activities of daily living (mADLs), and self-efficacy were completed. The calendar training group demonstrated significant improvement in mADLs compared to controls, while the computer training group did not. Calendar training may be more effective in improving mADLs than computerized intervention. However, this study highlights how behavioral trials with fewer than 30–50 participants per arm are likely underpowered, resulting in seemingly null findings.